Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologySierra Health and Life Entyvio IV Coverage Update …
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0053Q

    Entyvio (vedolizumab) — Intravenous infusion medical benefit policy

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0053Q alerts

    Get alerted when Policy 2026D0053Q changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical policy governing medical-benefit coverage and prior authorization criteria for intravenously administered Entyvio (vedolizumab) for UnitedHealthcare Commercial and Individual Exchange plans.

    Policy Summary
    Payersierra health and life
    PolicyEntyvio (vedolizumab) — Intravenous infusion medical benefit policy
    Policy CodePolicy 2026D0053Q
    Change TypeCriteria revised — initial and continuation therapy requirements updated
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document prior conventional therapy failure or prior systemic targeted immunomodulator treatment for initial Entyvio therapy.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage criteria were revised to require either prior failure of specified conventional therapies or prior treatment with a systemic targeted immunomodulator for initial therapy in Crohn's disease and ulcerative colitis.

    Continuation criteria now require that patients are not receiving Entyvio in combination with another systemic targeted immunomodulator for the same indication.

    Previous requirements for failure of at least one TNF blocker, immunomodulator, or corticosteroid for some indications were removed.

    List of systemic targeted immunomodulators that must not be used in combination with Entyvio was updated (e.g., Zeposia added; some agents removed).

    Policy template updated and Application section added specifying applicability to UnitedHealthcare Commercial and Individual Exchange benefit plans.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    indications with coverage criteria
    12 moIBD auth length
    3 dosesICI-related limit
    4 dosesGI aGVHD limit
    ~50+ICD-10 codes listed
    2026-08-01Policy effective

    Coverage Criteria for Entyvio (vedolizumab)

    Crohn's Disease

    Covered when ALL of the following are met

    CD initial therapy

    • Prior therapy options: History of failure to one conventional therapy at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced (corticosteroids such as prednisone, methylprednisolone, budesonide; 6‑mercaptopurine; azathioprine; methotrexate) OR patient has been previously treated with a systemic targeted immunomodulator FDA‑approved for Crohn's disease OR patient is currently on Entyvio therapy
    CD continuation: For continuation of therapy: documentation of positive clinical response to Entyvio; Entyvio dosing for Crohn's disease is in accordance with FDA‑labeled dosing; patient is not receiving Entyvio in combination with another systemic targeted immunomodulator for treatment of the same indication; reauthorization will be for no more than 12 months

    Crohn's Disease — Continuation

    For continuation of therapy, ALL of the following:

    CD continuation: Documentation of positive clinical response to Entyvio; Entyvio dosing for Crohn's disease is in accordance with FDA‑labeled dosing; patient is not receiving Entyvio in combination with another systemic targeted immunomodulator for treatment of the same indication; reauthorization will be for no more than 12 months

    Ulcerative Colitis

    Covered when ALL of the following are met

    UC initial therapy

    • Prior therapy options: Prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6‑mercaptopurine) OR patient has been previously treated with a systemic targeted immunomodulator FDA‑approved for ulcerative colitis OR patient is currently on Entyvio therapy
    UC continuation: For continuation of therapy: documentation of positive clinical response to Entyvio; Entyvio dosing for ulcerative colitis is in accordance with FDA‑labeled dosing; patient is not receiving Entyvio in combination with another systemic targeted immunomodulator for treatment of the same indication; reauthorization will be for no more than 12 months

    Ulcerative Colitis — Continuation

    For continuation of therapy, ALL of the following:

    UC continuation: Documentation of positive clinical response to Entyvio; Entyvio dosing for ulcerative colitis is in accordance with FDA‑labeled dosing; patient is not receiving Entyvio in combination with another systemic targeted immunomodulator for treatment of the same indication; reauthorization will be for no more than 12 months

    Immune Checkpoint Inhibitor–Related Toxicities

    Covered when ALL of the following are met

    ICI‑related toxicities initial: For initial therapy: one of the specified immunotherapy‑related diagnoses (moderate to severe esophagitis, gastritis, or duodenitis not improved on corticosteroids or budesonide; mild diarrhea/colitis if persistent or progressive with positive lactoferrin/calprotectin; or moderate to severe immunotherapy‑related diarrhea or colitis); patient is receiving a checkpoint inhibitor; AND one of the following: history of failure, contraindication, or intolerance to infliximab OR patient has immune‑related hepatitis; initial authorization will be for no more than 3 doses of Entyvio
    ICI‑related toxicities continuation: For continuation of therapy: documentation of positive clinical response; patient continues to experience checkpoint inhibitor‑related toxicities; reauthorization will be for no more than 3 doses of Entyvio

    Gastrointestinal Acute Graft‑Versus‑Host Disease

    Covered when ALL of the following are met

    GI aGVHD initial: For initial therapy: diagnosis of steroid‑refractory acute GI aGVHD; and one of the following: patient is receiving Entyvio in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; initial authorization will be for no more than 4 doses
    GI aGVHD continuation: For continuation of therapy: documentation of positive clinical response; patient continues to experience acute GI aGVHD; reauthorization will be for no more than 4 doses

    Crohn's Disease (CD) Initial Therapy

    Covered when ONE of the following is met:

    Initial CD criteria: Either: (1) history of failure to one of the listed conventional therapies at up to maximally indicated doses unless contraindicated (corticosteroids, 6‑mercaptopurine, azathioprine, methotrexate), or (2) patient has been previously treated with a systemic targeted immunomodulator FDA‑approved for Crohn's disease, or (3) patient is currently on Entyvio therapy.

    Entyvio must be prescribed by or in consultation with a gastroenterologist.

    Crohn's Disease Continuation of Therapy

    Covered when ALL of the following are met:

    Continuation CD: Documentation of positive clinical response to Entyvio and patient is not receiving Entyvio in combination with another systemic targeted immunomodulator for the same indication.

    Examples of systemic targeted immunomodulators are listed in the policy; Entyvio prescribed by or in consultation with a gastroenterologist.

    Ulcerative Colitis (UC) Initial Therapy

    Covered when ONE of the following is met:

    Initial UC criteria: Either: (1) prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6‑mercaptopurine), or (2) patient has been previously treated with a systemic targeted immunomodulator FDA‑approved for ulcerative colitis, or (3) patient is currently on Entyvio therapy.

    Entyvio must be prescribed by or in consultation with a gastroenterologist.

    Ulcerative Colitis Continuation of Therapy

    Covered when ALL of the following are met:

    Continuation UC: Documentation of positive clinical response to Entyvio and patient is not receiving Entyvio in combination with another systemic targeted immunomodulator for the same indication.

    Examples of systemic targeted immunomodulators are listed in the policy.

    Immune Checkpoint Inhibitor-Related Toxicities Continuation

    Covered when BOTH are met:

    ICI-related continuation: Documentation of positive clinical response and continued checkpoint inhibitor‑related toxicities; previous stricter diagnostic and treatment‑specific requirements were removed.

    Reauthorization will be for no more than 3 doses of Entyvio.

    Subcutaneous, self‑administered Entyvio (vedolizumab) is obtained under the pharmacy benefit unless the member's benefit plan documents specify otherwise. Exception: for members enrolled in UnitedHealthcare of California plans where a delegated provider group conducts the prior authorization review, the self‑administered formulation may be obtained under the medical benefit.

    Entyvio must not be used in combination with another systemic targeted immunomodulator for treatment of the same indication. Concurrent use with any of the listed systemic targeted immunomodulators (examples in policy include adalimumab, certolizumab, mirikizumab, upadacitinib, risankizumab, guselkumab, ustekinumab, among others) is an exclusion and may result in denial of coverage.

    Use of Entyvio without meeting the policy's specified initial therapy criteria — for example, when there is no documented history of required prior conventional therapies at maximally indicated doses (unless contraindicated) or no documentation of prior treatment with a systemic targeted immunomodulator where required — is considered not medically necessary. Similarly, requests for Entyvio while the patient is receiving another systemic targeted immunomodulator for the same indication are considered not medically necessary.

    Coding and Authorization Durations

    Applicable ICD-10 CodesICD-10
    D89.810Acute graft-versus-host disease
    K50.00Crohn's disease of small intestine without complications
    K50.011Crohn's disease of small intestine with rectal bleeding
    K50.012Crohn's disease of small intestine with intestinal obstruction
    K50.013Crohn's disease of small intestine with fistula
    K50.014Crohn's disease of small intestine with abscess
    K50.018Crohn's disease of small intestine with other complication
    K50.019Crohn's disease of small intestine with unspecified complications
    K50.10Crohn's disease of large intestine without complications
    K50.111Crohn's disease of large intestine with rectal bleeding
    1–10 of 36
    1/4
    Applicable ICD-10 Diagnosis CodesICD-10
    D89.810Acute graft-versus-host disease
    K50.00Crohn's disease of small intestine without complications
    K50.011Crohn's disease of small intestine with rectal bleeding
    K50.012Crohn's disease of small intestine with intestinal obstruction
    K50.013Crohn's disease of small intestine with fistula
    K50.014Crohn's disease of small intestine with abscess
    K50.018Crohn's disease of small intestine with other complication
    K50.019Crohn's disease of small intestine with unspecified complications
    K50.10Crohn's disease of large intestine without complications
    K50.111Crohn's disease of large intestine with rectal bleeding
    1–10 of 81
    1/9
    inv-17: Authorization duration (IBD)
    Authorization duration (IBD)Initial and reauthorization approvals up to 12 months.
    Applies toCrohn's disease and ulcerative colitis initial and continuation authorizations per policy criteria.
    Reauthorization requirementDocumentation of positive clinical response is required for reauthorization within the 12‑month limit.
    inv-18: Authorization duration (checkpoint inhibitor toxicities)
    Authorization duration (checkpoint inhibitor toxicities)Initial and reauthorization approvals up to 3 doses of Entyvio (e.g., weeks 0, 2, and 6 per guideline‑supported dosing).
    Initial criteria tie‑in

    Provider Requirements, Prior Authorization, and Denial Triggers

    Prior Authorization

    Prior authorization required for IV Entyvio (medical benefit)

    Prior authorization is required under the medical benefit for intravenous Entyvio for UnitedHealthcare Commercial and Individual Exchange plans; self‑administered subcutaneous Entyvio is obtained under the pharmacy benefit unless otherwise specified in the member's benefit plan documents (exception for delegated California plans).

    Prior Authorization

    Authorization requires documented prior therapies or prior targeted immunomodulator

    Prior authorization must follow the Medical Benefit Drug Policy: initial therapy approvals require documentation of either prior failure of the listed conventional therapies at up to maximally indicated doses, prior treatment with a systemic targeted immunomodulator, or that the patient is currently on Entyvio; continuation requires documentation of clinical response and that the patient is not receiving Entyvio in combination with another systemic targeted immunomodulator for the same indication.

    Definitions and Examples

    inv-30: GI acute graft‑versus‑host disease (aGVHD)
    DefinitionGI acute graft‑versus‑host disease (aGVHD): steroid‑refractory acute GI aGVHD.
    Initial therapy contextEntyvio is proven and medically necessary for steroid‑refractory acute GI aGVHD when patient is receiving Entyvio with systemic corticosteroids or is steroid‑intolerant.
    Authorization limitInitial and reauthorization approvals are limited to no more than 4 doses for this indication.
    inv-31: Immune checkpoint inhibitor–related toxicities
    DefinitionImmune checkpoint inhibitor–related toxicities: moderate to severe GI toxicities including esophagitis, gastritis, duodenitis, and diarrhea/colitis (including persistent/progressive mild [G1] disease with positive fecal markers) when refractory to corticosteroids/budesonide.
    Patient context

    Background

    Vedolizumab (Entyvio) is a humanized monoclonal antibody that binds the α4β7‑integrin, inhibiting migration of memory T‑lymphocytes into inflamed gastrointestinal tissue. It is indicated in this policy for treatment of moderately to severely active Crohn's disease and ulcerative colitis, and the policy also addresses use for immune checkpoint inhibitor–related GI toxicities and steroid‑refractory gastrointestinal acute graft‑versus‑host disease with specified dose limits and coverage criteria.

    Policy Revision History

    2026-08-01policy_revisedLatest

    Coverage criteria revised: initial therapy for Crohn's disease and ulcerative colitis now require either prior failure of specified conventional therapies or prior treatment with a systemic targeted immunomodulator; continuation criteria require no concurrent use of Entyvio with another systemic targeted immunomodulator for the same indication; lists of systemic targeted immunomodulators were updated (Zeposia added; some agents removed/renamed).

    2026-08-01template_update

    Policy template updated and Application section added to indicate applicability to UnitedHealthcare Commercial and Individual Exchange benefit plans; clarified that self-administered subcutaneous Entyvio is obtained under the pharmacy benefit unless plan specifies otherwise (exception for certain UnitedHealthcare of California delegated reviews).

    Policy Summary
    Payersierra health and life
    PolicyEntyvio (vedolizumab) — Intravenous infusion medical benefit policy
    Policy CodePolicy 2026D0053Q
    Change TypeCriteria revised — initial and continuation therapy requirements updated
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document prior conventional therapy failure or prior systemic targeted immunomodulator treatment for initial Entyvio therapy.
    SourceLink
    On This Page
    Coverage Criteria for Entyvio (vedolizumab)Coding and Authorization DurationsProvider Requirements, Prior Authorization, and Denial TriggersDefinitions and ExamplesBackgroundPolicy Revision History
    Initial authorization limited to no more than 3 doses when used for immune checkpoint inhibitor–related GI toxicities.
    Reauthorization requirementReauthorization requires documentation of positive clinical response and ongoing checkpoint inhibitor–related toxicities; reauthorization also limited to up to 3 doses.
    inv-19: Authorization duration (GI aGVHD)
    Authorization duration (GI aGVHD)Initial and reauthorization approvals up to 4 doses of Entyvio for steroid‑refractory acute GI aGVHD.
    Initial therapy noteInitial authorization will be for no more than 4 doses when used for steroid‑refractory acute GI aGVHD; may be given with systemic corticosteroids or when steroid intolerant.
    ContinuationReauthorization requires documentation of positive clinical response and ongoing acute GI aGVHD; reauthorization limited to up to 4 doses.
    inv-20: Conventional therapy failure
    Conventional therapy failure (required for initial IBD therapy)History of failure to one of the following at up to maximally indicated doses unless contraindicated: corticosteroids (e.g., prednisone, methylprednisolone, budesonide); 6‑mercaptopurine (Purinethol); azathioprine (Imuran); methotrexate (Rheumatrex, Trexall).
    Alternative prior therapy optionPrevious treatment with a systemic targeted immunomodulator FDA‑approved for the indication may substitute for conventional therapy failure when meeting initial therapy criteria.
    Current therapy exceptionPatient currently on Entyvio therapy satisfies initial therapy option for coverage continuation per policy language.
    Step Therapy

    Document prior failure/contraindication to conventional therapies or prior targeted therapy

    For Crohn's disease and ulcerative colitis initial therapy, the provider must document history of failure, contraindication, or intolerance to specified conventional immunomodulatory therapies (e.g., corticosteroids, 6‑mercaptopurine, azathioprine, methotrexate) OR prior treatment with a systemic targeted immunomodulator, or that the patient is currently receiving Entyvio.

    Step Therapy

    Step therapy: conventional therapy failure or prior systemic targeted immunomodulator

    Initial therapy criteria include step elements: either failure of one listed conventional therapy at up to maximally indicated doses unless contraindicated, or prior use of a systemic targeted immunomodulator; these function as required step(s) before IV Entyvio in many cases.

    Documentation Required

    Follow FDA dosing and involve a gastroenterologist for IBD

    Prescriptions must be initiated and titrated according to FDA‑labeled dosing; for Crohn's disease and ulcerative colitis, Entyvio must be prescribed by or in consultation with a gastroenterologist as required by the policy.

    Documentation Required

    Document prior therapies, current Entyvio use, and gastroenterology consultation

    Provider must document prior therapies (corticosteroids, immunomodulators, or systemic targeted immunomodulators) or indicate that the patient is currently on Entyvio therapy; documentation of gastroenterology consultation and member‑specific benefit plan should be referenced for benefit exceptions.

    Denial Risk

    Denial risk: concurrent systemic targeted immunomodulator or non‑compliant dosing/criteria

    Requests may be denied if Entyvio is prescribed in combination with another systemic targeted immunomodulator for the same indication, if FDA‑labeled dosing is not followed, or if the diagnosis/coverage criteria are not met.

    Denial Risk

    Denial triggers: missing prior‑therapy documentation or unauthorized prior targeted use

    Denial risks include failure to document inadequate response to the specified conventional therapies (at maximally indicated doses unless contraindicated) when required for initial therapy, or prior use of a systemic targeted immunomodulator without meeting the policy's initial‑therapy options; concurrent use of Entyvio with another systemic targeted immunomodulator for the same indication may also lead to non‑approval.

    Patient must be receiving a checkpoint inhibitor (e.g., pembrolizumab, nivolumab) for this indication per policy criteria.
    Prior therapy requirementInitial therapy requires prior failure, contraindication, or intolerance to infliximab OR presence of immune‑related hepatitis as specified in policy.
    inv-32: Vedolizumab (Entyvio)
    Mechanism of actionVedolizumab (Entyvio) is a humanized monoclonal antibody that binds α4β7‑integrin, blocking interaction with MAdCAM‑1 and inhibiting movement of memory T‑lymphocytes into inflamed gastrointestinal tissue.
    Therapeutic useUsed to reduce chronic GI inflammation in ulcerative colitis and Crohn’s disease and for specified off‑label GI immune indications as described in policy.
    Formulation notePolicy clarifies self‑administered subcutaneous Entyvio is obtained under the pharmacy benefit unless the member's plan specifies otherwise.
    inv-33: Systemic targeted immunomodulator (examples)
    ExamplesSystemic targeted immunomodulators referenced include: adalimumab; certolizumab (Cimzia); mirikizumab (Omvoh); upadacitinib (Rinvoq); risankizumab (Skyrizi); guselkumab (Tremfya); ustekinumab.
    Additional agents listed for UCPolicy examples for ulcerative colitis also include golimumab (Simponi), tofacitinib (Xeljanz/Xeljanz XR), and ozanimod (Zeposia) among referenced systemic agents.
    Combination restrictionEntyvio must not be used in combination with another systemic targeted immunomodulator for treatment of the same indication; concurrent use may result in non‑approval.